Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTA-H19 in superficial bladder cancer
NCT00393809Phase 2Completed
- Sponsor
- Hebrew University of Jerusalem
- Start
- Jan 2006
- Primary completion
- Nov 2007
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label trial of inodiftagene vixteplasmid in bladder cancer (5 arms), sponsored by Hebrew University of Jerusalem. Primary endpoint: Maximum Tolerated Dose. Started Jan 2006; status: completed.
02
Drugs
inodiftagene vixteplasmid
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00393809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00393809.